Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.

This is a retrospective review of 131I-MIBG therapy for metastatic neuroendocrine tumours in 25 adult patients. The tumours comprised 17 carcinoids, six paragangliomas, one somatostatinoma and one intestinal smooth muscle sarcoma. All patients (age range 28-84 years) had stage IV disease and a positive diagnostic 123I-MIBG scan. Patients received 11.1 GBq (300 mCi) of 131I-MIBG given in three cycles at 3-monthly intervals. The mean cumulative dose was 27.7 GBq (751 mCi). Symptomatic response was observed in 80%, hormonal response in 55% and tumour response in 48% (WHO criteria). Of the 25 patients, 40% are still under follow-up. Death was due to disease progression in all except one. The median survival time was 48 months from diagnosis of metastatic disease, and 17 months from the last 131I-MIBG therapy. The 5-year survival rate was 59% (95% confidence interval, 34%-78%). There was no statistical difference in survival between previously treated (chemo/radiotherapy) and treatment-naive patients. Side-effects were minimal and commonly include nausea (in the first 24 h) and a transient fall in platelet count. 131I-MIBG provides a good therapeutic response in patients with metastatic neuro-endocrine tumours.

[1]  A. Grossman,et al.  Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I‐metaiodobenzylguanidine , 1993, Nuclear medicine communications.

[2]  C. L. Le Rest,et al.  Functional imaging of malignant paragangliomas and carcinoid tumours , 2001, European Journal of Nuclear Medicine.

[3]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[4]  R. Bukowski,et al.  Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. , 1999, Current opinion in oncology.

[5]  Kvols Lk.  The carcinoid syndrome: a treatable malignant disease. , 1988 .

[6]  J. Beijnen,et al.  Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Kvols,et al.  Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. , 1995, Seminars in nuclear medicine.

[8]  B. Skogseid.  Nonsurgical Treatment of Advanced Malignant Neuroendocrine Pancreatic Tumors and Midgut Carcinoids , 2001, World Journal of Surgery.

[9]  C. Moertel.  Karnofsky memorial lecture. An odyssey in the land of small tumors. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  V. Rufini,et al.  131I-MIBG therapy of neural crest tumours (review). , 1997, Anticancer research.

[11]  K. Matthay,et al.  The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients , 1997, Journal of endocrinological investigation.

[12]  P. Ghaneh,et al.  (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  L. Kvols,et al.  Metastatic carcinoid tumors and the malignant carcinoid syndrome. , 1993, Acta oncologica.

[14]  A. Brunt,et al.  Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[15]  M. Gaze,et al.  Functional imaging as an aid to decision-making in metastatic paraganglioma. , 2001, The British journal of radiology.